DRTB-HDT - Stratified Host-Directed Therapy for Rifampicin-Resistant TB: A Randomized Controlled Multi-Centre Trial

Tuberculosis (TB) has historically been the most common infectious cause of death globally, surpassed only recently (and presumably temporarily) by the ongoing Covid-19 pandemic. TB treatment is lengthy and often unsuccessful. Even if cured, most patients are left with impaired lung function and…

01.01.2020 - 31.12.2025
Clinical Trial
European Commission (EU) / Horizon 2020
Clinical Research Unit
Klaus Reither
Performance of Cepheid GeneXpert® Omni for early detection of tuberculosis and multidrug resistant tuberculosis in adults with presumptive pulmonary tuberculosis at Primary Health Care facilities in Georgia in a controlled phased pre and post intervention

Tuberculosis (TB) still remains a major global challenge. In 2017, there were estimated10million new cases globally. Same year 16% of people with TB has died from the disease. In the same year, 6.4 million new cases were reported, accounting for only 64% of the total estimated incidence. Due to…

01.09.2019 - 31.12.2020
Intervention Study
Foundation for Innovative New Diagnostics (FIND ), Geneva, Switzerland
Clinical Research Unit
Klaus Reither